Under physiological conditions, expression of S1PR isoforms is tightly regulated in a tissue- and context-specific manner (11). In cancer, this architecture is frequently subverted by oncogenic and inflammatory signaling pathways that directly reshape receptor transcription (13,42). For example, IL-6-STAT3 signaling can induce S1PR1 transcription through promoter binding, thereby establishing a feedforward circuit that sustains aberrant STAT3 activation in tumor cells (18). Similarly, transforming growth factor-β (TGFβ)-mothers against decapentaplegic homolog 3 signaling upregulates S1PR3 in lung adenocarcinoma, promoting the EMT, migration and metastatic behavior (43).

By contrast, receptor subtypes with tumor-restraining functions are often transcriptionally suppressed. S1PR2 provides a prominent example (13). In diffuse large B cell lymphoma (DLBCL), forkhead box protein P1 (FOXP1) represses S1PR2 transcription, thereby relieving constraints on motility and proliferation (44). In other settings, viral oncogenesis may also indirectly alter receptor expression through changes in chromatin accessibility or promoter activity, as suggested for S1PR3 in Epstein-Barr virus-associated nasopharyngeal carcinoma (8,45). These observations indicate that tumor-associated signaling does not simply activate downstream pathways; it can selectively reshape the receptor landscape through transcriptional rewiring (8).

Epigenetic regulation provides an additional layer of control (8). DNA methylation, histone modification and chromatin remodeling can alter accessibility to S1PR loci and thereby reinforce malignant signaling states (8,46). In hematologic malignancies, disruption of the S1PR2 axis often occurs through multiple convergent mechanisms (47,48). In DLBCL, S1PR2 may be lost through recurrent mutations in the germinal center B cell-like subtype or through FOXP1-mediated repression in the activated B cell-like subtype (47). This loss can be further reinforced by hypermethylation of SMAD1, which impairs TGFβ-dependent induction of tumor-suppressive signaling (13,47). More broadly, nuclear S1P itself can influence chromatin regulation by inhibiting histone deacetylase (HDAC) 1 and HDAC2, thereby promoting histone acetylation and transcription of genes involved in cell-cycle control and survival (49). These findings place sphingolipid metabolism and chromatin regulation within the same regulatory framework and suggest that epigenetic remodeling is a central mechanism through which tumors reprogram receptor output (2,8).

Posttranscriptional mechanisms, particularly those mediated by miRNAs, are also important determinants of receptor abundance (50). Several tumor-suppressive miRNAs, including miR-148a, miR-363 and miR-133b, directly target the 3' untranslated region of S1PR1 mRNA and thereby limit receptor expression (12,50). Loss of these constraints can increase S1PR1 abundance and reinforce oncogenic phenotypes (51). In hepatocellular carcinoma, depletion of miR-148a promotes invasion and metastasis, whereas in nasopharyngeal carcinoma, downregulation of miR-133b was more strongly linked to proliferative signaling (50-52).

This regulatory logic extends across the receptor family (50). miR-9 suppresses both S1PR1 and S1PR3 and miR-125b is also reported to negatively regulate S1PR1 in lung carcinoma (53,54). In cancer, these interactions may be disrupted by genomic loss of miRNA loci, defective Dicer or Drosha processing, or repression by oncogenic signaling pathways (54,55). The result is not merely loss of fine-tuning, but a permissive state in which increased receptor abundance amplifies downstream signaling (54).

Other forms of posttranscriptional regulation may further stabilize this rewired state (42). Long non-coding (lnc)RNAs have been implicated in multidrug resistance and related oncogenic phenotypes, although their receptor-specific roles within the S1P axis remain less clearly defined (2,56). Taken together, these findings indicate that posttranscriptional deregulation can serve as a critical intermediate between oncogenic signaling and receptor overactivity, enabling tumors to sustain pathological S1P signaling even in the absence of direct genomic alterations (11,50).

Tumor-associated rewiring of the S1P-S1PR axis also occurs at the level of receptor trafficking, membrane organization and post-translational modifications (57,58). Under physiological conditions, receptor internalization and recycling help constrain signaling duration and preserve responsiveness to extracellular gradients (59). In cancer, these controls may be altered in ways that prolong receptor residence at the plasma membrane or otherwise favor sustained signaling output (57).

S1PR1 provides one example of this principle. Its localization within lipid raft or caveolin-enriched membrane domains is linked to receptor clustering, internalization and efficient downstream coupling. Disruption of this spatial organization may impair normal desensitization and favor persistent G protein-mediated signaling (59,60). Similarly, adaptor proteins such as phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 protein can interfere with agonist-induced receptor endocytosis and thereby prolong receptor signaling at the cell surface (57). These observations support the broader view that the strength of receptor signaling depends not only on how much receptor is expressed, but also on whether the receptor remains properly trafficked and spatially constrained (57,61).

Post-translational modifications add further complexity. N-Linked glycosylation is implicated in the efficient surface delivery and stabilization of S1PR1 and S1PR5 (60,62,63). Lipid modifications, particularly palmitoylation, may likewise promote receptor partitioning into signaling-competent membrane microdomains, thereby supporting efficient downstream coupling and pathway output (60,64). Emerging evidence also suggests that non-canonical forms of GPCR organization, including altered β-arrestin dynamics, may modulate S1PR desensitization in selected systems (57,59). Although these mechanisms remain less established than transcriptional or epigenetic reprogramming, they raise the possibility that tumors enhance signaling not only by increasing receptor expression levels but also by preserving receptors in a signaling-competent state (2,57).

Cancer cells may exploit the S1P-S1PR axis through two complementary strategies (11). The first is ectopic expression of receptor isoforms that are normally restricted to other tissues (34,35). The second is functional reactivation or stabilization of receptors that are already constitutively expressed but are normally subject to tighter regulatory control (18,57).

Examples of de novo receptor expression highlight how tumors can expand the signaling repertoire available to them (11). In T-cell large granular lymphocyte leukemia, aberrant induction of the S1PR5 lineage-restricted receptor is linked to constitutive ERK1/2 activation and enhanced pro-survival signaling, suggesting that acquisition of this receptor program may create a selective therapeutic vulnerability (62,65). Similarly, S1PR4, which is typically associated with hematopoietic tissues, can be induced in estrogen receptor-negative breast cancer, where it amplifies human epidermal growth factor receptor 2-linked signaling and correlates with a poor prognosis (2,35). In such settings, tumors do not simply intensify an existing signaling axis; they acquire receptor programs that are not normally part of the tissue context (34).

At the same time, S1PR1-S1PR3 can be functionally reprogrammed without requiring de novo expression (2). Ligand-rich tumor microenvironments, altered receptor trafficking and changes in membrane organization may all favor persistent activation of constitutively expressed receptors (11,57). In this way, tumors can strengthen signaling output either by acquiring new receptor modules or by stabilizing existing ones in a hyperactive state (34,57). This distinction between de novo receptor expression and functional reactivation provides a useful conceptual framework for understanding how cancers expand or intensify S1P signaling in different settings (11).

Persistent activation of the S1P-S1PR axis in cancer reflects the convergence of metabolic dysregulation and receptor-level rewiring (2,11). In numerous tumors, SphK1 is upregulated, increasing S1P production, whereas reduced activity of sphingosine-1-phosphate lyase promotes further accumulation of intracellular and extracellular S1P (8). These changes create ligand-rich conditions that favor chronic pathway activation, tumor progression, and therapeutic resistance (2).

However, ligand abundance alone does not fully explain the signaling output (11). Functional studies indicated that receptor abundance, localization and signaling competence are equally important determinants of pathway strength (57,59). In Epstein-Barr virus-positive nasopharyngeal carcinoma, for example, both elevated S1P and increased S1PR3 expression are required to drive migration and silencing S1PR3 markedly attenuates S1P-dependent effects (45). Likewise, in breast cancer, co-expression of S1P and S1PR1 establishes an autocrine signaling loop that promotes invasion and angiogenesis (2,18). These examples illustrate a broader principle: Tumors exploit both metabolic and receptor-level mechanisms to amplify signaling beyond what either mechanism could achieve alone (11).

This convergence has important conceptual and therapeutic implications (8). It suggests that the malignant consequences of S1P signaling emerge not simply from excess ligands, nor solely from altered receptor expression, but from coordinated rewiring of both (2,11). Accordingly, effective interventions may require simultaneous consideration of ligand production, the receptor state and cellular context (8).

Although the preceding sections emphasize that most tumor-associated rewiring of the S1P-S1PR axis is driven by non-genetic mechanisms, focal genomic alterations provide instructive exceptions that help clarify the oncogenic or tumor-suppressive functions of specific receptor isoforms (13,66). In most solid tumors, receptor dysregulation appears to predominantly arise through transcriptional, epigenetic, posttranscriptional, metabolic and post-translational reprogramming rather than through recurrent coding alterations (47). Even so, selected genetic lesions offer important insight into how individual receptors constrain or promote malignant behaviors in defined disease contexts (48).

The clearest example is S1PR2 in DLBCL, where recurrent loss-of-function mutations disrupt a tumor-suppressive signaling axis involved in growth control, cytoskeletal organization and tissue compartmentalization (48). These lesions often coexist with additional perturbations, including guanine nucleotide-binding protein subunit alpha-13 inactivation or SMAD1 loss, which further weaken receptor-dependent restraint (47,48). In this setting, genetic disruption of S1PR2 helps define a receptor program that normally limits malignant expansion and dissemination (48).

By contrast, S1PR3 amplification was described in ependymomas, where recurrent gain of the 9q22.1 locus, often together with SHC-transforming protein 3, promotes signaling programs linked to tumor growth and survival (67,68). Although this appears to be a more context-restricted event, it is consistent with the broader association of S1PR3 with aggressive and invasive phenotypes (69).

These examples are informative, but they do not define the dominant pattern across cancers (11). Rather, they underscore that although genomic lesions can shape receptor output in selected settings, most tumor-associated changes in the S1P-S1PR axis arise through non-genetic rewiring (2,47,66). Beyond these genetic exceptions, the broader reprogramming of the S1P-S1PR axis is likely sustained by interacting non-genetic regulatory layers. Transcriptional activation may be stabilized by epigenetic remodeling, whereas loss of miRNA-mediated repression can further increase receptor abundance once permissive chromatin states are established (42,70). In parallel, altered trafficking and posttranslational regulation may retain receptors in signaling-competent membrane compartments, allowing ligand-rich microenvironments to convert increased receptor abundances into sustained pathway activation (2,57). The S1P-S1PR axis is therefore most plausibly reprogrammed through convergent, mutually reinforcing layers of control rather than through any single dominant lesion, a framework that may help explain how modest changes across multiple levels collectively sustain oncogenic signaling and therapeutic resistance (2,11).

Pharmacological modulation of S1PRs represents one major strategy for therapeutic interventions (11). Several S1PR-targeting agents, initially developed or approved for autoimmune diseases, are now being explored for antitumor applications (Table II) (71,72). For example, the selective S1PR1/5 modulator, siponimod, is reported to overcome chemoresistance in ovarian carcinoma by suppressing S1PR1-dependent p-STAT3 signaling (73). Other studies link a receptor-directed intervention to inhibition of S1PR3-dependent AKT-ERK signaling in renal cell carcinoma or to suppression of metabolic programs such as Yes-associated protein-c-MYC signaling in osteosarcomas (74,75).

Next-generation compounds with greater receptor selectivity may offer additional advantages (76). ACT-209905, a selective S1PR1 modulator, has shown activity in glioblastoma models and can enhance sensitivity to temozolomide (77). Likewise, S1PR3 antagonists, including TY-52156 and related pepducins, have demonstrated anti-angiogenic and immunomodulatory effects in preclinical systems (28,78). These findings support the idea that receptor-selective targeting may interrupt discrete malignant signaling modules rather than broadly suppressing all S1P signaling (23,76).

As elevated S1P availability is a recurring driver of receptor activation, upstream metabolic targeting provides a complementary therapeutic approach (8). SphK1 is of particular interest given its frequent upregulation in cancer and its role in maintaining ligand-rich microenvironments (2). In principle, inhibition of SphK activity can attenuate both tumor cell-intrinsic and microenvironmental S1P signaling (12). Similarly, S1P-neutralizing strategies, including antibody-based approaches such as sphingomab, have shown antitumor activity in preclinical models (79).

This upstream approach is especially attractive within the framework advanced in the present review, because it addresses one major component of pathway reprogramming: Metabolic amplification of the ligand supply (2,8). However, metabolic targeting alone may be insufficient in settings where receptor abundance, receptor localization, or downstream coupling have also been rewired to favor persistent signaling (8,42).

The coordinated nature of S1P axis reprogramming argues strongly for combination approaches (42). If tumors exploit both increased ligand production and receptor-level rewiring, then simultaneous targeting of S1P synthesis and receptor-mediated signaling may produce more-durable pathway suppression than either approach alone (42). This concept is supported by experimental observations in which ligand availability and receptor expression cooperate to drive malignant phenotypes (35).

Combination strategies may also extend beyond the S1P pathway itself (42). Pairing S1PR-directed agents with chemotherapy, radiotherapy, targeted kinase inhibitors, or immune checkpoint blockade could prove particularly effective in tumors where S1P signaling contributes to therapeutic resistance, stromal crosstalk, or immune exclusion (12,80). Similarly, selective S1PR3 antagonism may complement immunotherapy by reducing macrophage polarization toward suppressive states and by mitigating T-cell exhaustion in selected settings (28). Although these approaches remain largely preclinical, they align closely with the reprogramming model developed in this review.

Despite its promise, therapeutic targeting of the S1P-S1PR axis is complicated by the physiological importance of this pathway in vascular and immune homeostasis (69). Even receptor-selective agents can produce organ-specific on-target toxicities, most notably bradycardia and macular edema (71,76). A distinct liability arises from interference with physiological lymphocyte trafficking, which may lead to functional immunosuppression rather than direct organ toxicity (11,76). These liabilities highlight the challenge of targeting a pathway whose physiological roles are closely intertwined with its pathological functions (23).

For this reason, future progress will depend not only on improved pharmacology but also on improved patient stratification (23). Biomarkers that capture receptor expression, ligand-rich states, transcriptional programs such as STAT3 activation, or immune-context features may help identify tumors most likely to benefit from pathway-directed interventions (12,28). More-selective agonists, antagonists, or biased modulators may further improve the therapeutic window by preferentially targeting disease-relevant signaling outputs while minimizing adverse effects linked to normal physiology (62,76).

Taken together, these considerations suggest that the most effective therapeutic strategies will likely be those that treat the S1P-S1PR axis not as a uniform pathway, but as a reprogrammed signaling network whose vulnerabilities vary across tumor types and biological contexts (13).